Purpose: The purpose of this study was to assess short-term efficacy and safety of tear promotion eye drops (biological tear substitutes and topical secretagogues) for treating dry eye disease.
Methods: Randomized controlled trials comparing short-term effects of biological tear substitutes or topical secretagogues versus placebo or other topical dry eye treatments in adults with dry eye disease were identified from the MEDLINE, Embase, Scopus, ClinicalTrials.gov , and World Health Organization International Clinical Trials Registry Platform databases. Pairwise meta-analysis and network meta-analysis were performed. Outcomes were ocular symptoms, ocular surface staining, tear break-up time, Schirmer test, and adverse events. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations approach.
Results: Thirty-nine randomized controlled trials (3693 patients) were eligible. Using artificial tears as a reference, autologous platelet lysate was the most effective treatment for lowering ocular surface disease index (unstandardized mean difference [USMD] -31.85; 95% confidence interval [CI]: -43.19 to -20.51) and platelet rich plasma showed the most reduction in corneal fluorescein staining scores (standardized mean difference -2.52; 95% CI: -3.23 to -1.82). Cord blood serum was the most effective treatment for increasing tear break-up time (USMD 2.67; 95% CI: 0.53-4.82), and eledoisin was superior to others in improving Schirmer scores (USMD 2.28; 95% CI: 0.14-4.42). Most interventions did not significantly increase ocular adverse events compared with artificial tears.
Conclusions: Biological tear substitutes, including autologous serum, autologous platelet lysate, platelet rich plasma, and cord blood serum, might be the most effective treatment among tear promotion eye drops in relieving dry eye symptoms without increasing adverse events. However, there remains uncertainty around these findings because of low/very low certainty of evidence.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365259 | PMC |
| http://dx.doi.org/10.1097/ICO.0000000000002943 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Overexpression of tear matrix metalloproteinases-9 (MMP-9) on the ocular surface tissues has been reported to result in ocular surface damage. MMP-9 levels in tears have been listed as one of many tools for confirming dry eye disease (DED).
Objective: This investigation aimed to compare MMP-9 levels and ocular surface parameters in diabetic patients with and without DED.
An update on emerging pharmacological treatments for meibomian gland dysfunction.
Expert Opin Pharmacother
January 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, Italy.
Introduction: Meibomian Gland Dysfunction (MGD) represents the most common cause of dry eye disease (DED). Traditional treatments mainly rely on heating and liquifying the meibum to favor its expression. However, recent knowledge advances have led to the development of novel therapies specifically designed for patients with MGD.
View Article and Find Full Text PDFEfficacy and safety of transient receptor potential channel modulators for dry eye: A systematic review and meta-analysis.
Cont Lens Anterior Eye
January 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China; Department of Integrative Medicine, Baoshan Campus of Huashan Hospital, Fudan University, Shanghai, China. Electronic address:
Purpose: To investigate the efficacy and safety of transient receptor potential (TRP) channel modulators for dry eye.
Methods: A thorough search for randomized clinical trials was conducted in seven databases up to February 16, 2024. Suitable studies were identified according to inclusion and exclusion criteria, extracted data were synthesized and analyzed using Review Manager 5.
Real-world analysis of medications inducing meibomian gland dysfunction: based on the FDA adverse event reporting system database.
Expert Opin Drug Saf
January 2025
Eye Institute & Affiliated Xiamen Eye Center, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Background: Dry eye syndrome (DES) has become a significant public health issue, impacting quality of life. Meibomian Gland Dysfunction (MGD) is a primary contributor to DES, and its etiology includes diverse factors. Given the potential for drug-induced MGD, comprehensive investigation into this association is crucial.
View Article and Find Full Text PDFPredicting autoimmune thyroiditis in primary Sjogren's syndrome patients using a random forest classifier: a retrospective study.
Arthritis Res Ther
January 2025
Scientific Research Project Department, Guangdong Artificial Intelligence and Digital Economy Laboratory (Guangzhou), Pazhou Lab, Guangzhou, China.
Article Synopsis
- The study examines how effective machine learning, particularly the Random Forest Classifier, is in predicting thyroid-specific autoantibodies in patients with Primary Sjogren's syndrome (pSS) based on clinical data.
- A total of 96 pSS patients were analyzed through thyroid function tests to categorize them by the presence of autoantibodies, leading to the exploration of various risk factors using four different machine learning algorithms.
- The Random Forest Classifier yielded the best results (AUC = 0.755), highlighting age, IgG levels, complement C4, and dry mouth as significant predictors for autoimmune thyroiditis in these patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!